Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETHZ NASDAQ:GRAY NYSE:IBIO NYSE:NBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$2.31-4.5%$0.00$0.66▼$17.75$14.61M0.3730.01 million shs8.03 million shsGRAYGraybug Vision$3.08-2.8%$2.68$5.00▼$22.12$8.64M1.22,165 shs33,051 shsIBIOiBio$0.84+2.9%$0.74$0.56▼$6.89$16.41M0.861.51 million shs365,979 shsNBYNovaBay Pharmaceuticals$3.73-11.6%$0.96$0.44▼$4.44$24.58M0.622.56 million shs9.49 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition-4.55%+230,999,900.00%+230,999,900.00%+230,999,900.00%+230,999,900.00%GRAYGraybug Vision0.00%+17.95%+7.33%+85.06%-35.98%IBIOiBio+2.92%+2.12%+40.34%-15.21%-54.62%NBYNovaBay Pharmaceuticals-11.61%+109.55%+531.35%+543.10%+691.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$2.31-4.5%$0.00$0.66▼$17.75$14.61M0.3730.01 million shs8.03 million shsGRAYGraybug Vision$3.08-2.8%$2.68$5.00▼$22.12$8.64M1.22,165 shs33,051 shsIBIOiBio$0.84+2.9%$0.74$0.56▼$6.89$16.41M0.861.51 million shs365,979 shsNBYNovaBay Pharmaceuticals$3.73-11.6%$0.96$0.44▼$4.44$24.58M0.622.56 million shs9.49 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition-4.55%+230,999,900.00%+230,999,900.00%+230,999,900.00%+230,999,900.00%GRAYGraybug Vision0.00%+17.95%+7.33%+85.06%-35.98%IBIOiBio+2.92%+2.12%+40.34%-15.21%-54.62%NBYNovaBay Pharmaceuticals-11.61%+109.55%+531.35%+543.10%+691.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETHZFlag Ship Acquisition 0.00N/AN/AN/AGRAYGraybug Vision 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00498.80% UpsideNBYNovaBay Pharmaceuticals 3.00Buy$0.85-77.21% DownsideCurrent Analyst Ratings BreakdownLatest GRAY, ETHZ, IBIO, and NBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETHZFlag Ship AcquisitionN/AN/AN/AN/A$2.91 per shareN/AGRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/AIBIOiBio$375K43.77N/AN/A$1.41 per share0.59NBYNovaBay Pharmaceuticals$9.78M2.22N/AN/A$4.25 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETHZFlag Ship Acquisition-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%N/AGRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ANBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETHZFlag Ship AcquisitionN/A0.580.58GRAYGraybug VisionN/A10.7310.72IBIOiBio0.051.761.76NBYNovaBay PharmaceuticalsN/A1.150.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETHZFlag Ship Acquisition4.07%GRAYGraybug Vision49.94%IBIOiBio7.90%NBYNovaBay Pharmaceuticals23.25%Insider OwnershipCompanyInsider OwnershipETHZFlag Ship Acquisition38.20%GRAYGraybug Vision7.94%IBIOiBio0.58%NBYNovaBay Pharmaceuticals0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETHZFlag Ship Acquisition76.04 million3.73 millionN/AGRAYGraybug Vision271.57 million20.25 millionNot OptionableIBIOiBio10019.66 million9.82 millionN/ANBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableGRAY, ETHZ, IBIO, and NBY HeadlinesRecent News About These CompaniesNovaBay Pharma Announces Special Cash DividendAugust 26, 2025 | msn.comNovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per ShareAugust 26, 2025 | finance.yahoo.comWhy Is NovaBay Pharmaceuticals Stock (NBY) Up 60% Today?August 20, 2025 | msn.comNovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarAugust 19, 2025 | globenewswire.comNBY NovaBay Pharmaceuticals, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comNovaBay Pharmaceuticals Inc. Stock Grades | NBY | Barron'sMay 26, 2025 | barrons.comNovaBay Pharmaceuticals approves liquidation planApril 24, 2025 | uk.investing.comNovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Acquires 21,654 SharesApril 16, 2025 | insidertrades.comNovaBay Pharmaceuticals Delays Yearly Report FilingApril 1, 2025 | tipranks.comNovaBay Pharmaceuticals to Hold Special Meeting of StockholdersMarch 7, 2025 | businesswire.comNovaBay fails to gain shareholder approval for dissolutionFebruary 5, 2025 | msn.comNovaBay Pharmaceuticals Inc NBYFebruary 1, 2025 | morningstar.comMNovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's WhyDecember 25, 2024 | zacks.comNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersDecember 19, 2024 | businesswire.comNovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special MeetingDecember 9, 2024 | businesswire.comNovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024November 22, 2024 | businesswire.comNovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase PriceNovember 6, 2024 | businesswire.comNovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick FactsSeptember 21, 2024 | markets.businessinsider.comNBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to ShareholdersSeptember 20, 2024 | businesswire.comAcumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsSeptember 20, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRAY, ETHZ, IBIO, and NBY Company DescriptionsFlag Ship Acquisition NASDAQ:ETHZ$2.31 -0.11 (-4.55%) As of 09/5/2025 04:00 PM Eastern1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Graybug Vision NASDAQ:GRAY$3.08 -0.09 (-2.84%) As of 09/5/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.iBio NYSE:IBIO$0.84 +0.02 (+2.92%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.83 -0.01 (-0.72%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NovaBay Pharmaceuticals NYSE:NBY$3.73 -0.49 (-11.61%) As of 09/5/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
